Galectin-3 regulates the expression of tumor glycosaminoglycans and increases the metastatic potential of breast cancer
Carregando...
Data
2019
Data de publicação:
Autores IPEN
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Journal of Oncology
ODS
Exportar
Resumo
Galectin-3 (Gal-3) is a multifunctional β-galactoside-binding lectin that once synthesized is expressed in the nucleus, cytoplasm,
cell surface, and extracellular environment. Gal-3 plays an important role in breast cancer tumors due to its ability to promote
interactions between cell-cell and cell-extracellular matrix (ECM) elements, increasing tumor survival and metastatic dissemination.
Still, the mechanism by which Gal-3 interferes with tumor cell migration and metastasis formation is complex and not
fully understood. Here, we showed that Gal-3 knockdown increased the migration ability of 4T1 murine breast cancer cells in vitro.
Using the 4T1 orthotopic breast cancer spontaneous metastasis mouse model, we demonstrated that 4T1-derived tumors were
significantly larger in the presence of Gal-3 (scramble) in comparison with Gal-3 knockdown 4T1-derived tumors. Nevertheless,
Gal-3 knockdown 4T1 cells were outnumbered in the bone marrow in comparison with scramble 4T1 cells. Finally, we reported
here a decrease in the content of cell-surface syndecan-1 and an increase in the levels of chondroitin sulfate proteoglycans such as
versican in Gal-3 knockdown 4T1 cells both in vitro and in vivo. Overall, our findings establish that Gal-3 downregulation during
breast cancer progression regulates cell-associated and tumor microenvironment glycosaminoglycans (GAGs)/proteoglycans
(PG), thus enhancing the metastatic potential of tumor cells.
Como referenciar
PEREIRA, JONATHAS X.; SANTOS, SOFIA N. dos; PEREIRA, THAIS C.; CABANEL, MARIANA; CHAMMAS, ROGER; OLIVEIRA, FELIPE L. de; BERNARDES, EMERSON S.; EL-CHEIKH, MARCIA C. Galectin-3 regulates the expression of tumor glycosaminoglycans and increases the metastatic potential of breast cancer. Journal of Oncology, v. 2019, p. 1-15, 2019. DOI: 10.1155/2019/9827147. Disponível em: http://repositorio.ipen.br/handle/123456789/30836. Acesso em: 19 Apr 2024.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.